News | July 10, 2022
Sirio Pharma announces agreement to acquire best formulations
The combined company will be able to better serve both our global and regional customers with local production
The combined company will be able to better serve both our global and regional customers with local production
Themis Medicare’s VIRALEX is an effective and safe drug for management of mild to moderate COVID and other acute viral respiratory infections.
Domestic devices are usually preferred over imported medical devices in the national or regional procurement.
AbTis will have access to WuXi XDC's integrated services for linker and payload manufacturing
.jpg)
Evonik's six innovation growth fields are: Sustainable nutrition, healthcare solutions, advanced food ingredients, membranes, cosmetic solutions, and additive manufacturing
Site Enhances New Modality CRDMO Platform Capacity for Customers
The acquisition continues the growth and expansion course of the ALPLApharma business division established in 2019
Fermentation-based manufacturing leverages Evonik’s biotechnology platform
The US FDA has determined that the inspection classification of the facility is Voluntary Action Indicated
The new facility will be delivered through an investment of approximately CHF 500 million and is expected to be completed in 2026
Subscribe To Our Newsletter & Stay Updated
